Omega Therapeutics (OMGA)
(Delayed Data from NSDQ)
$2.07 USD
-0.18 (-8.00%)
Updated Jul 2, 2024 04:00 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Income Statements
Fiscal Year end for Omega Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 3 | 2 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 3 | 2 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 103 | 105 | 66 | 29 | 0 |
Income After Depreciation & Amortization | -100 | -103 | -66 | -29 | 0 |
Non-Operating Income | 3 | 0 | -1 | 0 | NA |
Interest Expense | 0 | 0 | 1 | 1 | NA |
Pretax Income | -97 | -103 | -68 | -29 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -97 | -103 | -68 | -29 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -97 | -103 | -68 | -29 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -93 | -98 | -65 | -27 | 0 |
Depreciation & Amortization (Cash Flow) | 7 | 5 | 1 | 1 | NA |
Income After Depreciation & Amortization | -100 | -103 | -66 | -29 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 54.01 | 47.88 | 22.40 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.80 | -2.14 | -3.05 | NA | NA |
Diluted Net EPS (GAAP) | -1.80 | -2.14 | -3.05 | NA | NA |
Fiscal Year end for Omega Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 2.36 | 0.99 | 0.83 | 0.76 | 0.52 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 2.36 | 0.99 | 0.83 | 0.76 | 0.52 |
SG&A, R&D, and Dept/Amort Expenses | 22.82 | 21.87 | 23.74 | 31.60 | 26.34 |
Income After SG&A, R&D, and Dept/Amort Expenses | -20.46 | -20.88 | -22.91 | -30.84 | -25.82 |
Non-Operating Income | 0.32 | 0.00 | -0.03 | 0.20 | -0.14 |
Interest Expense | 0.00 | 2.32 | -0.68 | -0.96 | -0.68 |
Pretax Income | -20.13 | -20.21 | -22.25 | -29.69 | -25.28 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -20.13 | -20.21 | -22.25 | -29.69 | -25.28 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -20.13 | -20.21 | -22.25 | -29.69 | -25.28 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 55.15 | 55.14 | 55.14 | 55.07 | 50.63 |
Diluted EPS Before Non-Recurring Items | -0.36 | -0.37 | -0.40 | -0.54 | -0.50 |
Diluted Net EPS (GAAP) | -0.36 | -0.36 | -0.40 | -0.54 | -0.50 |